Header image

Concurrent Session 3A: From Evidence to Early Adoption: What will it take to deliver LADB access in LMICs

Tracks
.
Thursday, October 8, 2026
11:15 AM - 12:15 PM
Zenit

Details

Since INHSU 2025, global momentum around long-acting depot buprenorphine (LADB) in low- and middle-income countries (LMICs) has grown significantly. New implementation research findings, country readiness signals, and early market-shaping efforts are helping clarify what it will take to translate promise into practice. This session will build directly on prior discussions at INHSU and include both foundational evidence and practical pathways for early introduction and scale. Speakers will share updated evidence, lessons from early adopter countries, community-led introduction, and progress on financing – including Global Fund Grant Cycle 8, regulatory, and market-enabling mechanisms. The session will also explore how global and national actors can work together to ensure equitable, sustainable access to LADB as a harm reduction and hepatitis prevention tool. The aim is to move the conversation from why LADB matters to how access can realistically happen in LMICs.


Speaker

Dr Kimberly Green
Global Program Director, Primary Health Care
PATH

Opening remarks: Framing LADB as an additional choice for OAMT and recent WHO recommendation

11:15 AM - 11:20 AM

Biography

Dr Kimberly Green
Global Program Director, Primary Health Care
PATH

Initial evidence from LADB studies in LMICs on acceptability, feasibility, effectiveness, cost-effectiveness

11:20 AM - 11:28 AM

Biography

Agenda Item Image
Dr Annie Madden
Project Lead
International Network of People Who Use Drugs (INPUD)

Initial evidence from LADB studies in LMICs on acceptability, feasibility, effectiveness, cost-effectiveness

11:20 AM - 11:28 AM

Biography

Maria Phelan
Senior Technical Advisor: Key Populations
The Global Fund

Guidance on how countries can include LADB in Global Fund Funding Requests

11:28 AM - 11:36 AM

Biography

Agenda Item Image
Mr. Kanishk Gupta
Market Shaping Officer
PATH

Overview of pricing, regulatory and demand planning for LADB in LMICs

11:36 AM - 11:44 AM

Biography

Market Shaping Officer at PATH and a product introduction and market access specialist with 15 years of experience. His current work focuses on expanding access to hepatitis and harm reduction products for people who inject drugs across low- and middle-income countries. He contributes to market assessments, demand forecasting, investment cases, manufacturer engagement, and introduction strategies for hepatitis C diagnostics and treatment, low dead space syringes and needles, and opioid agonist therapies, including long-acting injectable buprenorphine.
Agenda Item Image
Dr Raghda Algamil
Director of Addiction Treatment Administration
Ministry of Health- General Secretariat of Mental Health and Addiction. , Egypt

Panel Discussion: What it takes to move from LADB pilots to programs: Country Ministry of Health, community, WHO and funders perspectives

11:44 AM - 12:10 PM

Biography

Agenda Item Image
Ms Victoria Goodfellow
Head Of Infectious Diseases
Medaccess

Panel Discussion: What it takes to move from LADB pilots to programs: Country Ministry of Health, community, WHO and funders perspectives

11:44 AM - 12:10 PM

Biography

Victoria Goodfellow is a senior health financing expert with over two decades of experience across healthcare financing and investment banking. Victoria has focused largely on expanding access to essential health commodities in sub-Saharan Africa, through roles spanning system-level financing, innovative finance and the procurement of medicines and diagnostics for infectious diseases. At MedAccess, Victoria is Head of Infectious Diseases. She works with partners to identify opportunities where innovative finance can overcome barriers to accessing health innovations. Victoria holds a Master’s in International Health Policy (Health Economics) from the London School of Economics and a Bachelor of Economic Science from the University of Manchester.
Agenda Item Image
Dr Dzmitry Krupchanka
Medical Officer
WHO

Panel Discussion: What it takes to move from LADB pilots to programs: Country Ministry of Health, community, WHO and funders perspectives

11:44 AM - 12:10 PM

Biography

Dr Dzmitry Krupchanka is a Medical Officer at the Alcohol, Drugs and Addictive Behaviours Unit (ADA), Department of Mental Health, Brain Health and Substance Use (MSD) of the World Health Organization (WHO). In this role he is responsible for implementing a range of activities in prevention, treatment and care of disorders due substance use, addictive behaviours and related health conditions. This includes contribution to WHO normative guidance and technical support to countries, generation, and dissemination of evidence through international research projects, workforce development, monitoring and evaluation, enhancing joint efforts and advocacy in the area of alcohol, drugs and addictive behaviours. Dzmitry is a medical doctor and psychiatrist by professional background (Belarusian State Medical University, Belarus) with a MSc degree in Global Mental Health (University of London, UK) and PhDs in Clinical Psychiatry and Global Health (University of Geneva, Switzerland).
Abou Mere
Cab Member
HepC3P Global Community Advisory Board (CAB)

Panel Discussion: What it takes to move from LADB pilots to programs: Country Ministry of Health, community, WHO and funders perspectives

11:44 AM - 12:10 PM

Biography

Agenda Item Image
Dr Kingsley Michael
Assistant Director, Head of Harm Reduction and Hepatitis Component And Viral Hepatitis Component
National HIV/AIDS, Viral Hepatitis And STIs Control Programme, Federal Ministry of Health And Social Welfare (FMOHSW)

Panel Discussion: What it takes to move from LADB pilots to programs: Country Ministry of Health, community, WHO and funders perspectives

11:44 AM - 12:10 PM

Biography

Agenda Item Image
Ms Vielta Parkhomenko
Cab Member
HepC3P Global Community Advisory Board (CAB)

Panel Discussion: What it takes to move from LADB pilots to programs: Country Ministry of Health, community, WHO and funders perspectives

11:44 AM - 12:10 PM

Biography

Ms Catherina Timmermans
Technical Manager, Strategy
Unitaid

Closing Remarks: Key insights and shared priorities toward increasing choice for OAMT in LMICs

12:10 PM - 12:15 PM

Biography

loading